Education
About Us
Working with TipRanks
Follow Us
Genelux Corp. (GNLX)
NASDAQ:GNLX
GNLX Stock Chart & Stats
$7.71
-$0.06(-2.24%)
At close: 4:00 PM EST
$7.71
-$0.06(-2.24%)
Day’s Range― - ―
52-Week Range$1.99 - $6.52
Previous CloseN/A
Volume23.79K
Average Volume (3M)156.94K
Market Cap
$245.91M
Enterprise Value$82.64M
Total Cash (Recent Filing)$27.97M
Total Debt (Recent Filing)$1.71M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 12, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding37,773,440
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue92.23
Enterprise Value/Gross Profit-139.12
Enterprise Value/Ebitda-2.71
Forecast
1Y Price Target
$22.50Price Target Upside191.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressGenelux announced positive initial data from its investigator-sponsored ongoing P1b/2 study evaluating systemically administered Olvi-Vec + platinum chemotherapy in patients with platinum-relapsed or platinum-refractory small cell lung cancer.
Financial PositionThe company announced an equity financing for $10.5M in gross proceeds, which combined with its cash estimate should provide runway into 2026, through the P2 interim in NSCLC and potentially the top-line P3.
Regulatory MilestonesFDA alignment on adding interim overall survival analysis to the progression-free survival primary endpoint in the ovarian cancer trial could support full approval without the need for additional confirmatory trials.
Bears Say
Financial PerformanceGenelux reported a net loss, which may indicate financial challenges despite having a cash runway expected to last into the second half of 2026.
Market CompetitionInitial efficacy with Olvi-Vec + platinum is considered differentiated compared to previous treatments, which have shown lower response rates and progression-free survival.
Operational ChallengesThe company initiated dose escalation at lower doses than initially planned due to positive initial data at lower doses in small cell lung cancer.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $1.99 and its highest was $6.52 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $245.91M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Nov 12, 2025 which is in 18 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Aug 07, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.216 by $0.016.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.21.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 37,773,440 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.216. Following the earnings report the stock price went down -5.689%.
Which hedge fund is a major shareholder of Genelux Corp.?
Among the largest hedge funds holding Genelux Corp.’s share is Highbridge Capital Management LLC. It holds Genelux Corp.’s shares valued at 0.
Genelux Corp. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (191.83% Upside)
$22.50 (191.83% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.72%
12-Months-Change
Fundamentals
Return on Equity
-98.72%
Trailing 12-Months
Asset Growth
-28.62%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corp. (GNLX) is a biotechnology company focused on developing innovative cancer therapies using its proprietary gene therapy platform. The company specializes in oncolytic virus therapies, which are designed to selectively target and destroy cancer cells while sparing normal tissues. Genelux is advancing its lead product candidates through clinical trials, aiming to provide new treatment options for patients with various types of cancer. The company is primarily engaged in the biotechnology sector, emphasizing research and development of cutting-edge therapies that address unmet medical needs.
GNLX Stock 12 Month Forecast
Average Price Target
$22.50
▲(191.83% Upside)
Technical Analysis
Coherus Biosciences
―
Fate Therapeutics
―
Tonix Pharma
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Ownership Overview
14.62% Insiders
4.73% Mutual Funds
1.75% Other Institutional Investors
75.49% Public Companies and
Individual Investors